ChemoSNiP

When a drug is administered to the body, the body responds to the drug itself. Not every patient responds to chemotherapy identically. ChemoSNiP is a medical test that uses an advanced scientific technique called pharmacogenomics to analyze how a patient’s body will respond to a specific drug.

ChemoSNiP analyzes a blood sample to identify single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs, and other agents.

ChemoSNiP provides clinicians with a powerful insight into which drugs are most effective at treating cancer. The results provide a personalized analysis that can be used to provide the most effective combination of drugs and treatments available.

How does ChemoSNiP work?

• The human body commonly has variants that make us different from one another. These variants are called SNPs or single nucleotide polymorphisms. SNPs can make us respond differently to chemicals (drugs) when administered to the body.
• These are also responsible for the metabolism / detoxification of cytostatic or targeted drugs used in cancer therapy.
• ChemoSNiP examines these potential SNPs which affect how our body manages a drug, providing an exclusion criterion for chemotherapy that either may not work well or end up being excessively toxic to the body. It thus helps clinicians make superior personalized decisions on medication would work best and even modify dosages to prevent excessive toxicity.

Why choose the ChemoSNiP test?

• With molecular biology-based assays, ChemoSNiP has the effectiveness to locate and analyze the SNPs.
• The study of SNPs helps indicate which chemotherapeutic treatments would benefit the patient with the least risk of adverse side effects.
• Provides insights and personalized analysis of drugs and treatments for each patient.